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Abstract
Background: Berberine (BBR), a natural alkaloid compound, is used as a non-prescription drug in China for treating
diarrhea and gastroenteritis. Many studies have revealed that BBR possesses anticancer effect. However, the
molecular mechanisms underlying its anticancer action is far from being fully elucidated. This study is aimed to
determine the effect of BBR on the hedgehog (Hh) activity and the growth of cancers addiction to Hh activity.
Methods: The Hh activity was determined by dual luciferase assays and quantitative RT-PCR analyses. The growth
inhibition of BBR on medulloblastoma which was obtained from ptch+/−;p53−/− mice was analyzed by 5-bromo-2-
deoxyuridine (Brdu) assays and by allografting the medulloblastoma into nude mice. The data were statistically
analyzed by one-way analysis of variance (ANOVA), and multiple comparison between the groups was performed
using Dunnett’s method.
Results: In this study, we found that BBR significantly inhibited the Hh pathway activity. Meanwhile, we observed
that BBR failed to affect the transcriptional factors activities provoked by tumor necrosis factor-α (TNF-α) and
Prostaglandin E2 (PGE2), thus suggesting its unique property against Hh pathway activity. Further studies revealed
that BBR inhibited the Hh pathway activity by potentially targeting the critical component Smoothened (Smo) and
most likely shared the same binding site on Smo with cyclopamine, a classical Smo inhibitor. Finally, we
demonstrated that BBR obviously suppressed the Hh-dependent medulloblastoma growth in vitro and in vivo.
Conclusion: Collectively, our study uncovered a novel molecular mechanism responsible for the anticancer action
of BBR, thus opening the way for the usage of BBR for therapeutics of cancers addiction to aberrant Hh pathway
activity.
Background
Hh signaling pathway is an evolutionarily conserved sig-
naling axis of embryonic patterning and tissue homeo-
stasis [1, 2]. Deregulated activity of the Hh signaling
pathway has also been shown to be involved in the de-
velopment of tumors which arise sporadically or in gen-
etically predisposed individuals. In vertebrates, three Hh
ligands (Sonic hedgehog, Shh; Indian hedgehog, Ihh;
Desert hedgehog, Dhh) have been identified that bind to
the 12-transmembrane cell surface receptor Patched1
(PTCH1). When not bound by Hh ligands, PTCH1
restrains the activity of Smo, a member of the 7-
transmemebrane cell surface receptor. However, upon
bound by a ligand, PTCH1 no longer inhibits Smo,
thus allowing the accumulation of Smo in the primary
cilium. Ultimately, canonical Hh signaling regulates
the activity, proteolytic processing, and the stability of
the Gli family transcriptional factors, Gli1-3, and sub-
sequently initiates the transcription of Gli-dependent
target genes, such as Gli1 and ptch1 [3]. This regula-
tion requires a number of protein kinases, including
protein kinase A, glycogen synthase kinase 3 and ca-
sein kinase 1, and the negative regulator suppressor
of fused (SuFu) [4].
The mechanisms responsible for the constitutive Hh
pathway activity in cancers include ligand-independent and
ligand-dependent manner. Ligand-independent constitutive
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activation of Hh pathway in cancers is characterized by
somatic mutations in Ptch1, Smo, or Sufu, consequently
increasing Hh pathway activity and leading to a higher
incidence of basal cellular carcinoma (BCC) and me-
dulloblastoma. On the other hand, aberrant Hh path-
way activity in a wide range of cancers is associated
with elevated Hh ligands secretion from tumors or the
stromal environment, namely ligand-dependent manner
[2, 5]. Large-scale efforts have been made to develop
Hh pathway antagonists for treatment of cancers. As a
central regulator of the pathway and a readily accessible
cell surface component, Smo has been the most suc-
cessful target for developing Hh antagonists. There are
currently nine novel Smo inhibitors in clinic trial [6, 7].
Among them, vismodegib has been approved for treat-
ing in advanced unresectable BCC in 2012 [8].
BBR (chemical structure shown in Fig. 1a), a natural
isoquinoline alkaloid, can be isolated from the rhizome,
roots and stem barks of various important medicinal
plants, the Berberis species. BBR exhibits multiple
pharmacological activities, such as antimicrobial, antidia-
betic, cardioprotective effects [9]. Additionally, it has
been shown that BBR may inhibit the growth of a variety
of human cancer cell lines, including prostate [4, 10],
colon cancer [11], lung cancer [12, 13], nasopharyngeal
cancer [14], breast cancer [15, 16], and leukemia cells
[17]. However, the molecular mechanisms underlying
the anticancer effect of BBR remain far from being fully
elucidated. In this study, we identified that BBR may se-
lectively inhibit the Hh signaling pathway activity by tar-
geting Smo and consequently the Hh-dependent cancer
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Fig. 1 BBR inhibits Hh pathway activity in vitro. a Chemical structure of BBR. b BBR inhibited the Gli luciferase activity provoked by ShhN CM and
SAG. NIH-3 T3 cells transfected with luciferase reporter plasmids containing 8 × Gli binding sites and Renilla-TK plasmids were exposed to ShhN
CM or SAG supplemented with various concentrations of BBR for 36 h. The cells were lysed for the dual luciferase reporter activity analysis. The
firefly luciferase activity was normalized by the Renilla luciferase activity. The results are expressed as means ± s.d. from three independent
experiments (n = 3). (c-d) BBR inhibited the mRNA expressions of Gli1 provoked by ShhN CM (c) and SAG (d). NIH-3 T3 cells were treated with
ShhN CM or SAG with or without various concentrations of BBR for 24 h and harvested for RT-qPCR analysis. Data are expressed as mean ± s.d.
(n = 3). Experiments were repeated for three times. e BBR inhibited alkaline phosphatase activity in C3H10T1/2 cells. C3H10T1/2 cells were treated
with or without ShhN CM supplemented with various concentrations of BBR for 72 h. The results are expressed as mean ± s.d. from three
independent experiments (n = 3)
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mechanisms responsible for the anticancer action of
BBR and contributing to the future usage of BBR as an
anticancer drugs.
Methods
Cell lines and culture
The NIH-3T3 and C3H/10T1/2 mouse embryo fibro-
blast cells, HEK-293T human epithelial kidney cells, and
LS174T colon cancer cells were obtained from the
American Type Culture Collection (Manassas, VA). All
these cells were routinely cultured according to the
manufacturer’s instructions.
The variant containing the N-terminal signaling do-
main of the Shh (Shh) conditioned medium (CM) were
prepared as previously described [18]. Briefly, 293 T cells
(5 × 106) were seeded in 10-cm dishes. The plasmid har-
boring the ShhN were transfected into 293 T cells with
Lipofectamine 2000 reagent (Invitrogene; Grand Island,
NY). The medium (5 ml) in the cells were replaced with
fresh medium with 0.1 % serum 24 h post transfection.
After 24, the ShhN CM were collected, and were diluted
100-fold prior to be used for experiments.
Reagents and antibodies
BBR and PGE2 were obtained from Sigma-Aldrich (St.
Louis, MO). The Hh pathway antagonists cyclopamine,
GANT61, itraconazole, and BODIPY-cyclopamine were
obtained from Biovision (Milpitas, CA). The Hh path-
way agonist SAG was obtained from Selleck Chemicals
(Houston, TX). TNF-α, BAY 11–8072 and H89 were
purchased from Beyotime (Suzhou, China). Primary
antibodies against Smo, Gli2, and Sufu and GAPDH
were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA).
Plasmids and lentivirus
The 8 × Gli1-binding site luciferase reporter (8 × GBS-lu-
ciferase) plasmid was a kind gift from Dr. Hiroshi Sasaki.
The TCF/LEF-luciferase reporter plasmid, NF-κB –lucif-
erase reporter plasmid, and TK-Renilla luciferase plas-
mid were purchased from Promega (Madison, WI). The
Gli2 lacking the N-termianl (Gli2ΔN) plasmid and ShhN
plasmids were obtained from Addgene (Cambridge,
MA). The Myc-DKK-tagged ORF clone of Homo sapiens
Smo plasmid was purchased from Origene (Rockville,
MD). The mutant human plasmid SmoM2 (W535L) was
generated from wild type Smo plasmids using Quick-
Change Site-Directed Mutagenesis kit from Agilent
(Santa Clara, CA) and was confirmed by sequencing.
The Sufu-shRNA was purchased from Santa Cruz (Santa
Cruz, CA).
Transient transfections were performed using Lipofec-
tamine 2000 reagent from Invitrogen according to the
manufacturer’s instructions. The lentiviral stocks were
prepared according to previous report [19]. Briefly, the
plasmid carrying the Sufu-shRNA and three packaging
plasmids were co-transfected into 293T cells using Lipo-
fectamine 2000. The viruses were harvested 24 h post
transfection and 4 ml viruses were used for infected
NIH-3T3 cells seeded in 10-cm dishes. Infected cells
were analyzed 5–7 days post infection by western blot
analyses of the expression of Sufu.
Dual luciferase assays
Cells transfected with luciferase reporter plasmids con-
taining respective binding-sites of various transcriptional
factors and Renilla-TK construct were seeded into 48-
well plates. After various treatments as indicated, lucifer-
ase assays were conducted using a dual luciferase assay
kit according to the manufacturer’s instructions (Pro-
mega) on a luminometer (Molecular Device; Sunnyvale,
CA). The firefly luciferase values were normalized to
Renilla values.
Reverse transcription and quantitative polymerase chain
reaction (RT-qPCR)
Total RNA was extracted from cells or medullbolbatoma
tissues using Trizol reagent (Takara; Dalian, China) fol-
lowing the manufacturer’s protocol. The qPCR analyses









The mRNA levels of interested genes were normalized
to those of GUSB.
Western blot analysis
NIH-3T3 cells were harvested for western blot analysis
of the expression of Smo, Gli2, and Sufu according to
standard procedure. The blots of GAPDH were used as
loading controls.
Alkaline phosphatase activity assay
C3H10T1/2 cells were plated into 96-well plates at a
density of 5000 cells per well. After treatment with or
without ShhN CM supplemented with various concen-
trations of BBR for 72 h. The alkaline phosphatase activ-
ity was measured using a kit from Beyotime on a plate
reader (Molecular Device) at 405 nm.
Wang et al. BMC Cancer  (2015) 15:595 Page 3 of 9
Fluorescent BODIPY-cyclopamine competition assay
The 293T cells were seeded onto coverslips coated with
poly-D-lysine in 24-well plates, followed by transfection
with hSMO construct. After exposed to 1 uM BODIPY-
cyclopamine supplemented with or without various
compounds as indicated for 10 h, the cells were washed
with PBS, fixed with paraformaldehyde (4 %; v/v) for
10 min, incubated with a 0.1 % Triton X-100 for 15 min.
The cells were then subjected to fluorescence-activated
cell sorting (FACS; Becton Dickinson; San Jose, CA) ana-
lysis or were mounted with DAPI and visualized using a
fluorescence microscope (Leica; Wetzlar, Germany).
Medulloblastoma cells culture and Brdu assay
Medulloblastoma cells were obtained from medulloblas-
toma allografts by mechanical dissociation and viable
cell fractioning. The cells were maintained in Neurobasal
A medium (Invitrogen) containing B-27 supplement
(Invitrogen), epidermal growth factor 20 ng/ml (Invitro-
gen), basic fibroblastic growth factor 20 ng/ml (Invitro-
gen), nonessential amino acids (Invitrogen), N-acetyl
cysteine 60 mg/ml, and Glutamax (Invitrogen) [20].
Medulloblastoma cells were seeded into 96-well plates,
followed by treatment with various concentrations of
BBR for 36 h. The Brdu assays were conducted using the
Brdu Cell Proliferation Kit (Merck Millipore; Bedford,
MA) according to manufacturer’s instructions.
Medulloblastoma allograft model
Primary intracranial medulloblastoma from Ptch+/−;
p53−/− mouse [21, 22], which was obtained by crossing
ptch+/− mice (Jackson Laboratory; Harbor, MI) with
p53−/− mice (Jackson Laboratory), were harvested and
allografted subcutaneously into right and left flanks of
athymic nude mice (Beijing HFK Bio-Technology;
Beijing, China). The well-developed tumors were har-
vested, cut into 1 mm3 fragments and inoculated sub-
cutaneously into the right flank of athymic nude mice
using a trocar. When the tumor volume reached 100–
150 mm3, the mice were randomly assigned into control
and treatment group (n = 8). Control group was given
vehicle alone, and treatment group received BBR
(100 mg/kg) via oral gavage once daily for 3 weeks. The
volume of the tumors were measured twice per week
using microcaliper. The tumor volume (V) was calcu-
lated as following: V = [length(mm) × width2(mm2)]/2.
The individual relative tumor volume (RTV) was calcu-
lated as following: RTV = Vt/V0, where Vt is the volume
on each day, and V0 represents the volume at the begin-
ning of the treatment. All animal experiments in this
study were pre-approved by the Animal Care and Use
Committee of the Fudan University and performed ac-
cording to institutional policies.
Statistical analysis
Statistical differences were analyzed by one-way
ANOVA and P < 0.05 was considered as significant.
Multiple comparison between the groups was per-
formed using Dunnett’s method. (#p > 0.05; *P < 0.05,
**P < 0.01, *** < 0.001).
Results
BBR inhibits Hh signaling in vitro
To determine whether BBR can inhibit the Hh signaling,
NIH-3T3 cells, which have good response to the Hh
stimulation [23], transfected with 8 × Gli1-binding site
dependent firefly luciferase and Renilla Luciferase plas-
mids were stimulated with ShhN CM with or without
various concentrations of BBR. We observed that BBR
obviously inhibited the Gli-responsive reporter activity
provoked by ShhN CM in a dose-dependent manner
(Fig. 1b), with an IC50 value of 4.6 ± 1.2 μM. Concomi-
tantly, BBR reduced the mRNA expression of Gli1
(Fig. 1c), a transcriptional target of Gli, which served as
a readout of Gli activity. Moreover, we found that BBR
treatment also abolished the Gli luciferase activity
(Fig. 1b) and Gli1 mRNA abundance (Fig. 1d) provoked
by SAG, a small molecular compound agonist of Smo
[24]. To further determine the ability of BBR of sup-
pressing the Hh pathway activity, we conducted the alka-
line phosphatase activity assay using C3H10T1/2 cells,
which can express osteogenesis marker alkaline phos-
phatase when treated with Hh ligands [25, 26]. As shown
in Fig. 1e, exposure of BBR obviously suppressed the
alkaline phosphatase activity evoked by ShhN CM in
C3H10T1/2 cells. The inhibitory effect of BBR on the al-
kaline phosphatase activity was not due to the non-
specific cytotoxic activity of BBR, as BBR had no effect
on the cell numbers of C3H10T1/2 cells after BBR treat-
ment for 72 h (data not shown). Hence, our data show
that BBR may significantly inhibit the Hh signaling
in vitro.
BBR displays selectivity for inhibiting Hh pathway activity
To rule out the possibility that BBR nonspecifically in-
hibits Gli luciferase activity provoked by ShhN CM, we
examined the effect of BBR on other transcriptional fac-
tors, such as NF-κB, and TCF/LEF [27]. As shown in
Fig. 2a-b, we observed that tumor necrosis factor α
(TNF-α) and Prostaglandin E2 (PGE2) obviously pro-
voked the NF-κB, and TCF/LEF luciferase activity, while
BBR exhibited no inhibitory activity against either NF-
κB, or TCF/LEF luciferase activity stimulated by TNF-α
and PGE2. The BAY 11-7082, and H89 were used as
positive controls for inhibition of NF-κB, and TCF/LEF
luciferase activity, respectively (Fig. 2a-b). We have dem-
onstrated that PGE2 may activate the Gli activity in a
noncanonical manner (data to be published). We then
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asked whether BBR may suppress the Gli activity pro-
voked by PGE2. Interestingly, BBR failed to inhibit the
Gli luciferase activity activated by PGE2 (Fig. 2c). How-
ever, the GANT61, a small molecule inhibitor targeting
Gli [28], abundantly reduced the Gli luciferase activity
stimulated by PGE2 (Fig. 2c). Hence, our data demon-
strate that BBR exhibits unique property for suppressing
Hh signaling pathway activity.
BBR inhibits the Hh signaling pathway activity by
targeting Smo
Having demonstrated that BBR may specifically inhibit
the Hh signaling pathway activity, we then set out to de-
termine the molecular target of BBR for inhibiting Hh
pathway activity. We first tested whether BBR may sup-
press the Gli luciferase activity provoked by ectopic ex-
pression of Gli. As shown in Fig. 3a, overexpression of
Gli2ΔN (Fig. 3a, upper panel), a Gli2 variant missing
328 N-terminal amino acids, in the NIH-3T3 cells obvi-
ously stimulated the Gli-luciferase activity. However,
BBR had no inhibitory effect on the Gli luciferase activ-
ity provoked by Gli2ΔN, while the Gli small molecular
compound inhibitor GANT61 (Fig. 3a), which was used
as a positive control, significantly suppressed the Gli lu-
ciferase activity. Thus, these observations ruled out the
possibility that BBR inhibited the Hh signaling pathway
activity by targeting Gli. Moreover, BBR also failed to
affect the Gli-luciferase activity provoked by limiting the
expression of Sufu (Fig. 3b), a negative regulator of Hh
signaling pathway [28], suggesting that BBR inhibited
the Hh pathway activity by acting upstream of Sufu.
Based on these findings, we asked whether BBR inhib-
ited the Hh pathway activity by targeting Smo, which is
the most successful molecular target for developing anti-
cancer drugs in Hh pathway. To this end, we examined
the effect of BBR on the Gli-luciferase activity stimulated
by ectopic expression of Smo in NIH-3T3 cells N
(Fig. 3c, upper panel). BBR obviously inhibited the Gli-
luciferase activity stimulated by ectopic expression of
Smo (Fig. 3c), with the IC50 value (5.1 ± 3.4 μM) similar
to that for inhibiting the Gli-luciferase activity stimu-
lated by ShhN CM (4.6 ± 1.2 μM). However, BBR exhib-
ited little effect on the Gli-luciferase activity stimulated
by SmoM2 (Fig. 3d), a frequent mutant found in cancers
[29]. These data suggest that BBR inhibits the Hh path-
way activity potentially through targeting Smo.
Furthermore, as shown in Fig. 1b, d, we saw that BBR
also significantly inhibited the Gli-luciferase activity
(Fig. 1b) and Gli1 mRNA expression (Fig. 1d) provoked
by SAG, a small molecular compound agonist of Smo
[24]. Interestingly, the IC50 value of BBR for inhibiting
the Gli-luciferase activity provoked by ShhN CM (4.6 ±
1.2 μM.) is lower than that for inhibiting Gli-luciferase
activity provoked by SAG (8.7 ± 1.2 μM). Given that
SAG and cyclopamine bind to the same site on Smo
[24], these data suggest that BBR functions as a competi-
tive inhibitor with SAG and most likely share the same
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Fig. 2 BBR displays selectivity for inhibiting Hh pathway activity. a The 293 T cells transfected with luciferase reporter activity containing NF-κB
binding sites and Renilla-TK plasmids were exposed to TNF-α with BAY 11-872 or various concentrations of BBR for 6 h, and the cells were
harvested for dual luciferase reporter activity analysis. The data are expressed as mean ± s.d., (n = 3) from three independent experiments. b The
LS174T cells transfected with luciferase reporter constructs containing TCF/LEF binding sites and the Renilla-TK plasmids were exposed to PGE2
with various concentrations of BBR or H89 for 24 h, and the cells were collected for dual luciferase reporter activity analysis. The results are
expressed as means ± s.d. from three independent experiments (n = 3). c The LS174T cells transfected with luciferase reporter constructs
containing Gli binding sites and the Renilla-TK plasmids were exposed to PGE2 with various concentrations of BBR or GANT61 for 24 h, and the
cells were collected for dual luciferase reporter activity analysis. Data are expressed as means ± s.d. from three independent experiments (n = 3).
*p < 0.05; #p > 0.05
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strengthen this argument, we used the BODIPY-
cyclopamine, a fluorescent cyclopamine derivative,
assay. We observed that the binding of BODIPY-
cyclopamine to Smo was significantly suppressed by
BBR, similar to cyclopamine, which herein served as a
positive control (Fig. 3e). However, itraconazole, a
Smo inhibitor binding to Smo on a distinct binding
site from that of cyclopamine [20], failed to affect the
binding of BODIPY-cyclopamine to Smo (Fig. 3e). These
observations were further confirmed by FACS analysis
(Fig. 3f). Taken together, our data demonstrate that BBR
acts on Smo to inhibit the Hh pathway.
BBR inhibits the Hh-dependent medulloblastoma cell
growth in vitro
Having characterized the Hh pathway inhibitory activity
of BBR, we examined the effect of BBR on the growth of
Hh-dependent medulloblastoma cells isolated from me-
dulloblastoma in ptch+/−;p53−/− mice [21, 22]. Brdu
assay revealed that BBR dose-dependently inhibited the
A B E control BODIPY-cyclopamine
BODIPY-cyclopamine
+cyclopamine (5 μM) 
BODIPY-cyclopamine
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Fig. 3 BBR inhibits the Hh signaling pathway activity by potentially targeting Smo. a BBR had no effect on the Gli luciferase activity stimulated by
ectopic expression of Gli2△N. NIH-3 T3 cells transfected with Gli2△N, Gli luciferase reporter and the Renilla-TK constructs were treated with
GANT61 and various concentrations of BBR for 36 h. GFP was used as a control for Gli2△N. The results are expressed as mean ± s.d. from three
independent experiments (n = 3). b BBR exhibited no effect on the Gli luciferase activity provoked by knockdown of Sufu. NIH-3 T3 cells were
infected with lenti-virus harboring Sufu shRNA or shRNA control (the inserts shows the efficacy of knockdown by western blot analysis). The cells
were further transfected with Gli luciferase reporter and the Renilla-TK constructs, and exposed to GANT61 or BBR for 36 h. Data are expressed as
means ± s.d. (n = 3). (c-d) BBR significantly inhibited the Gli luciferase activity provoked by ectopic expression of Smo (c), while exhibited no effect
on that provoked by ectopic expression of SmoM2 (d). NIH-3 T3 cells were transfected with Smo or SmoM2, Gli luciferase reporter and the
Renilla-TK constructs were treated with various concentrations of BBR. GFP were used as a control for Smo or SmoM2. The results are expressed
as mean ± s.d. from three independent experiments (n = 3). e BODIPY-cyclopamine competition analysis. Photographs are representatives from
three distinct experiments. 293 T cells transfected with hSMO expression construct were exposed to 1 μM BODIPY-cyclopamine supplemented
with or without cyclopamine, itraconazole or BBR for 10 h. The cells were then mounted with DAPI and photographed. Photographs are
representatives from three distinct experiments (f). BODIPY-cyclopamine bound to Smo in 293 T cells as monitored by FACS analysis. #p > 0.05
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growth of medulloblastoma cell growth (Fig. 4a), con-
comitantly with comparable reduction of the mRNA ex-
pression of Gli1, and ptch1 (Fig. 4b, c), which served as
a readout of the Hh pathway activity. Hence, our data
show that BBR may inhibit the Hh-dependent medullo-
blastoma cells growth in vitro through inhibiting the Hh
pathway activity.
BBR inhibits the Hh-dependent medulloblastoma growth
in vivo
To further demonstrate that BBR may inhibit the growth
of the Hh-dependent medulloblastoma growth, we allo-
grafted the medulloblastoma isolated from ptch+/−;p53
−/− mice into the Nude mice. BBR was administrated by
gavage by 100 mg/kg daily. Consistent with the in vitro
data, BBR significantly inhibited the medulloblastoma
growth (Fig. 5a), which is accompanied with similar
reduction of the mRNA expression of Gli1 (Fig. 5b), and
ptch1 (Fig. 5c). Hence, our in vivo data further demon-
strate that BBR may inhibit the growth of Hh-dependent
medulloblastoma growth by inhibiting the Hh pathway
activity.
Discussion
BBR has strong anti-inflammatory and antimicrobial ac-
tivities. Owing to its excellent safety characteristics, BBR
has been used as a non-prescription drug to treat diar-
rhea and gastroenteritis in China since 1950s. Accumu-
lating reports show that BBR also possesses anti-cancer
effects, being able to suppress the proliferation of cancer
cells [9]. Previous studies have revealed various potential
molecular targets responsible for the anticancer actions
of BBR, such as DNA topoisomerase [30], HIF-1α [31],
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Fig. 4 BBR suppresses the proliferation of medulloblastoma cells in vitro. a BBR suppressed the proliferation of medulloblastoma cells analyzed by
Brdu assay. Medulloblastoma cells were treated with various concentrations of BBR for 36 h. Data are expressed as means ± s.d. from three
independent experiments (n = 3). (b-c) BBR suppressed the Gli1 mRNA (b) and ptch1 mRNA (c) expression in medulloblastoma cells.
Medulloblastoma cells were exposed to various concentrations of BBR for 24 h, and the cells were collected for RT-qPCR analysis. The results are



















































































Fig. 5 BBR inhibits the growth of medullboblastoma in vivo. a Inhibitory effect of BBR on the growth of medulloblastoma in vivo. Nude mice
allografted with medulloblastoma were administered the BBR 100 mg/kg by daily gavage for 21 days. RTV for indicated days was shown as mean
± s.d. for each group of mice. (b-c) BBR inhibited the Gli1 mRNA (b) and ptch1 mRNA (c) expression in the medulloblastoma tissues isolated from
nude mice. Four hours after last dose of BBR administration, the medulloblastom tissues were harvested for RT-qPCR analysis. Data are expressed
as mean ± s.d. *p < 0.05
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that BBR may selectively suppress the Hh signaling path-
way activity by potentially targeting the critical component
Smo, and consequently inhibit the Hh-dependent cancer
growth. Therefore, our study improve our knowledge
about the underlying molecular mechanisms behind the
anticancer actions of BBR, thus contributing to the future
usage of BBR for treating cancers driven by aberrant Hh
pathway activity.
This study shows that BBR displays specificity when
inhibiting Hh pathway activity, as reflected by no inhibi-
tory effects of BBR on the NF-κB, TCF/LEF and Gli aci-
tivity in response to TNF-α and PGE2. However, other
labs have shown that BBR may suppress the NF-kB ac-
tivity which consequently induces the apoptosis of mul-
tiple myeloma cells or protects against neuronal damage
via suppression of glia-mediated inflammation in trau-
matic brain injury [32, 33]. This discrepancy between
our observation and those from other labs [32, 33] may
be due to the distinct concentrations of BBR used. The
maximum concentration used in the present study was
20 μM, while the concentrations which had inhibitory
effect on the NF-κB activity in the studies from other
labs ranged from 50 to 100 μM [32, 33].
Addiction of tumors to Hh signaling pathway for
growth and metastasis has been verified with various Hh
pathway inhibitors. The natural teratogenic compound
cyclopamine, the first identified Hh pathway inhibitor,
blocks Hh pathway by directly binding to Smo, slowing
down tumor growth in animal models [34]. However,
concerns were raised on its anticancer efficacy due to
the off-target potential [35]. Moreover, the limited po-
tency and poor oral solubility hinders its clinical devel-
opment. Other more potent and selective Smo inhibitors
with diverse chemical structures have been developed
and are being investigated in clinical trials in a large
range of advanced and metastatic cancers, such as vis-
modegib, sonidegib, BMS-833923, PF04449913 and
LY2940680 [7]. Vismodegib has been approved for treat-
ment of advanced BCC in 2012 [8], therefore underpin-
ning the Smo as a molecular target for treating cancers.
Among all these Smo inhibitors, the majority share the
same binding site in Smo with cyclopamine, with the ex-
ceptions of itraconazole and several other antagonists
newly discovered by Tao et al. [36]. In the present study,
we identified that BBR can inhibit the Hh pathway activ-
ity by targeting Smo. We further identified that BBR
may most likely bind Smo at the same pocket with
cyclopamine, as reflected by competition of BBR for
binding to Smo with SAG and BODIPY-cyclopamine. Of
course, we cannot exclude the possibility that Smo acts
on Smo indirectly via another molecule, as lacking direct
binding assay. Hence, further verification of this argu-
ment by direct binding assay will help us to understand
the characteristics of the BBR action on Smo.
Conclusion
In summary, this study shows that BBR may selectively
inhibit the Hh pathway activity functioning as a Smo in-
hibitor potentially most likely by binding the same site
in Smo with cyclopamine. Using the ptch+/−;p53−/−
medulloblastoma model, we also demonstrate that BBR
significantly inhibit the Hh-dependent tumor growth by
inhibiting Hh pathway activity. Given that BBR has been
used as a non-prescription drug in China for decades,
and it has a good safety profile, it should be possible for
us to quickly investigate its clinical efficacy on patients
with tumors dependent on the Hh pathway by either
alone or in combination with other treatment strategies.
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